Donald Bellgrau
Oprichter bij ApopLogic Pharmaceuticals, Inc.
Profiel
Donald Bellgrau is the founder of GlobeImmune, Inc. (founded in 1995) and ApopLogic Pharmaceuticals, Inc. (founded in 2006).
At ApopLogic Pharmaceuticals, Inc., he holds the title of Director & Founding Scientist.
Currently, Dr. Bellgrau is a Professor at The University of Colorado.
In the past, he worked as a Member-Scientific Staff at the Basel Institute for Immunology.
He obtained his doctorate degree from the University of Pennsylvania.
Actieve functies van Donald Bellgrau
Bedrijven | Functie | Begin |
---|---|---|
The University of Colorado | Corporate Officer/Principal | 14-09-2009 |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Oprichter | 01-01-2006 |
Eerdere bekende functies van Donald Bellgrau
Bedrijven | Functie | Einde |
---|---|---|
GLOBEIMMUNE, INC. | Oprichter | - |
Basel Institute for Immunology | Corporate Officer/Principal | - |
Opleiding van Donald Bellgrau
University of Pennsylvania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GLOBEIMMUNE, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |